⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

December 1, 2026

Economic evaluation of perioperative pembrolizumab plus standard of care as treatment for resectable locally advanced head and neck squamous cell carcinoma in the United States.

Feng Qian Arielle G. Bensimon Anjela Tzontcheva K. Benjamin Ravindra Uppaluri D R Adkins Geoffrey B. Johnson Catherine Fernan Dandan Zheng Yuexin Tang Biruk Chafamo Dominic Muston

View at Publisher

Ask AI

Bookmark

Share

Key Points

This research evaluates the economic effectiveness of perioperative pembrolizumab in conjunction with standard care.
Economic evaluation comparing pembrolizumab plus SOC against SOC alone
Focus on treatment for resectable locally advanced head and neck squamous cell carcinoma
Assessment based on cost-effectiveness metrics
Pembrolizumab plus standard care is found to be cost-effective
Effective for patients with resectable locally advanced head and neck squamous cell carcinoma
CPS ≥ 1 criteria establishes the patient selection

Implication

Economic evaluation shows pembrolizumab is cost-effective compared to standard care for resectable head and neck cancer.

Abstract

Perioperative pembrolizumab + SOC was found to be cost-effective versus SOC for the treatment of resectable LA HNSCC with CPS ≥ 1.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Qian et al. (2026) studied this question.

synapsesocial.com/papers/699f95951bc9fecf3dab3803 https://doi.org/10.1080/13696998.2026.2633930

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Cost-Effectiveness of Perioperative Pembrolizumab in Locally Advanced Head and Neck CancerOriginal Research · 2026
2Combined Positive Score and Cost-Effectiveness of Perioperative Pembrolizumab for Head and Neck CancerHuman Clinical Trial · 2026 · 1 citations
3Cost-effectiveness of pembrolizumab as neoadjuvant therapy and in combination with standard of care (SOC) as adjuvant therapy for stage III-IVA resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC) in SwitzerlandCost-Effectiveness Analysis · 2026
4Perioperative immune checkpoint inhibition in head and neck squamous cell carcinoma: a 10-year reviewLate-Phase Clinical Trial · 2026
5Postoperative adjuvant immunotherapy versus standard of care in resectable locally advanced head and neck squamous cell carcinoma with intermediate- and high-risk factors: a real-world retrospective study2025 · 1 citations

EFFECT-neo: A phase 3 study of pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant therapy in patients with resectable locally advanced head and neck squamous cell carcinoma.2024
Effectiveness and cost-effectiveness of pembrolizumab in persistent, recurrent, or metastatic cervical cancer with PD-L1 CPS 1-10: secondary analysis of KEYNOTE-826 using innovative KMSubtraction2026
Safety and Efficacy of Pembrolizumab With Chemoradiotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma: A Phase IB Study2020

More from Harvard University

More from Brigham and Women's Hospital

More from Washington University in St. Louis

More from Dana-Farber Cancer Institute

More from Merck & Co., Inc., Rahway, NJ, USA (United States)

More from Analysis Group (United States)